Raily Aesthetic Medicine International Holdings Limited Provided consolidated unaudited earnings guidance for the year ended 31 December 2022. For the period, the Board expects the Group to record a revenue of approximately RMB 165 million (2021: revenue of approximately RMB 188 million) and expects to record a loss attributable to owners of the parent of approximately RMB 16 million (2021: loss of approximately RMB18 million).
Raily Aesthetic Medicine International Holdings Limited
Equities
2135
KYG7356A1215
Healthcare Facilities & Services
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.15 HKD | +3.45% | +14.50% | -68.75% |
04-19 | Raily Aesthetic Medicine International Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
03-07 | Raily Aesthetic Medicine Forecasts Wider Loss in 2023 | MT |
1st Jan change | Capi. | |
---|---|---|
-68.75% | 10.34M | |
-19.34% | 16.51B | |
+5.41% | 12.53B | |
+4.64% | 11.74B | |
+2.21% | 10.06B | |
+29.17% | 8.71B | |
-3.46% | 7.57B | |
+18.60% | 7.14B | |
+4.93% | 6.68B | |
+44.78% | 4.54B |
- Stock Market
- Equities
- 2135 Stock
- News Raily Aesthetic Medicine International Holdings Limited
- Raily Aesthetic Medicine International Holdings Limited Provides Consolidated Unaudited Earnings Guidance for the Year Ended 31 December 2022